Spark Therapeutics (ONCE) PT Lowered to $61 at SunTrust Robinson Humphrey

Spark Therapeutics (ONCE) PT Lowered to $77 at Barclays

Barclays lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $77.00 (from $85.00) while maintaining a Overweight rating.

BMO Capital Downgrades Spark Therapeutics (ONCE) to Market Perform

BMO Capital downgraded Spark Therapeutics (NASDAQ: ONCE) from Outperform to Market Perform with a price target of $60.00 (from $98.00).

For an analyst ratings summary and ratings history on Spark Therapeutics click here. For more ratings news on Spark Therapeutics click here.

Shares of Spark Therapeutics closed at $77.61 yesterday.

Spark Therapeutics (ONCE) PT Lowered to $80 at Cowen

Cowen lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $80.00 (from $90.00) while maintaining a Outperform rating.

Analyst Phil Nadeau commented, "Spark reported Q2 financials and provided an update on the SPK-8011 clinical program. Five of seven patients treated with... More

Spark Therapeutics (ONCE) PT Lowered to $64 at RBC Capital

RBC Capital lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $64.00 (from $75.00) while maintaining a Sector Perform rating.

Analyst Kennen MacKay said the view today's SPK-8011 update suggestive of efficacy and safety below investor expectations and expect the stock to be choppy into ASH data detailing today's update.

UPDATE: Credit Suisse Double Downgrades Spark Therapeutics (ONCE) to Underperform

(Updated - August 7, 2018 2:36 PM EDT)

(updated to add analsyt comments)

Credit Suisse downgraded Spark Therapeutics (NASDAQ: ONCE) from Outperform to Underperform with a price target of $48.00 (from $98.00).

Analyst Martin Auster said the company lacks catalysts to drive significant... More

UPDATE: Citi Upgrades Spark Therapeutics (ONCE) to Buy, Sees M&A Value Upwards of $130/Share

(Updated - August 7, 2018 11:58 AM EDT)

(updated to add analyst comment and price target)

Citi upgraded Spark Therapeutics (NASDAQ: ONCE) from Neutral to Buy, price target $85.00.

Analyst Mohit Bansal comments "While Spark is down ~30% after this AMs Hemophilia A update, we... More

Cantor Fitzgerald Defends Spark Therapeutics (ONCE), Saying They Didn't Expect Perfection

Cantor Fitzgerald analyst Elemer Piros came out to defended Spark Therapeutics (NASDAQ: ONCE) following data, saying while the market expected perfection, they didn't.

Piros commented, "We reiterate our Overweight rating and 12-month PT of $103 on Spark Therapeutics following 2Q18 financial results and program... More

Pre-Open Movers 08/07: (VCEL) (MNK) (TWLO) Higher; (ONCE) (GEMP) (ZG) Lower (more...)

Today's Pre-Open Movers

Spark Therapeutics (NASDAQ: ONCE) 29.7% LOWER; concerns about Hemophilia A Gene Therapy Data

Gemphire Therapeutics Inc. (NASDAQ: GEMP) 21.7% LOWER; announced that the U.S. Food and Drug Administration (FDA) has requested that the... More

BioMarin Pharma (BMRN) Climbs Following Hemophilia A Gene Therapy Data from Rival Spark Therapeutics (ONCE)

BioMarin Pharma (NASDAQ: BMRN) Climbs Following Hemophilia A Gene Therapy Data from Rival Spark Therapeutics (NASDAQ: ONCE)

Spark Therapeutics (ONCE) Reports Q2 Loss Per Share of $2.07

(Updated)

Spark Therapeutics (NASDAQ: ONCE) reported Q2 EPS of ($2.07), $1.97 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $25.2 million versus the consensus estimate of $29 million.

As of July 13, 2018, preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A... More